Fig. 1

For each of three categories: recurrent and hyper mutated regions (RHM, red, 832 total mutations), non-recurrent hypermutated regions (HM, green, 20958 total mutations), and other regions (OR, blue, 10713694 total mutations), we show the percent of mutations within region that belong to different cancer types. Malignant lymphoma has a disproportionate share of hypermutated regions, suggesting that our method of identifying hypermutated regions is capturing some regions that are targets of somatic hypermutation in this cohort. We define a region to be hypermutated when it has > 1.2 mutations per tumour, and to be recurrently mutated when it has a recurrence score greater than 10